Literature DB >> 31056250

Liver Transplantation After Downstagings of Ruptured Advanced Hepatocellular Carcinoma in Cirrhotic Liver: Is It Advisable? A Case Report.

Kuo-Shyang Jeng1, Chun-Chieh Huang2, Chien-Chu Lin3, Cheng-Kuan Lin3, Chung-Jen Teng4, Kuo-Hsin Chen5.   

Abstract

Spontaneous rupture of hepatocellular carcinoma (HCC), defined as T4 in TNM stage by the American Joint Committee on Cancer (eighth edition), is a serious life-threatening complication. Effective treatment remains challenging because of a high 1-month mortality, a short median survival, and the potential of peritoneal metastasis. We reported on a case that received a living related donor liver transplantation (LDLT) after successful consecutive downstaging therapies. A 63-year-old man with alcohol-related liver cirrhosis and multiple HCC developed spontaneous rupture and hemoperitoneum. He received 3 sessions of transcatheter hepatic arterial chemoembolization and target therapy with sorafenib. Computed tomography scans and magnetic resonance imaging after 11 months of treatment showed that the patient's HCCs fulfilled the Milan criteria and the University of California San Francisco criteria prior to LDLT. The perioperative course was rather smooth. After discharge, interval follow-up computed tomography studies of chest and liver and a whole-body bone scan showed no tumor recurrence or metastasis up to 20 months post-operation. Successful downstaging therapies of ruptured HCC to fulfill Milan criteria to receive liver transplantation is advisable in highly selected patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31056250     DOI: 10.1016/j.transproceed.2019.01.125

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Development and validation of risk score for predicting spontaneous rupture of hepatocellular carcinoma.

Authors:  Feng Ye; Di Ma; Xiao-Yong Gong; Yu-Chen Yang; Yong-Jun Chen
Journal:  Ann Surg Treat Res       Date:  2020-10-28       Impact factor: 1.859

2.  Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study.

Authors:  Yun Huang; Zeyu Zhang; Weijun Liao; Kuan Hu; Zhiming Wang
Journal:  Front Oncol       Date:  2021-08-02       Impact factor: 6.244

Review 3.  Neoadjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Lei Xu; Lin Chen; Wei Zhang
Journal:  World J Gastrointest Surg       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.